Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
APLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.98 - $44.12
Previous CloseN/A
Volume215.04K
Average Volume (3M)2.66M
Market Cap
$2.40B
Enterprise Value$4.03B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 11, 2025EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding125,682,260
10 Day Avg. Volume2,548,720
30 Day Avg. Volume2,660,373
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-26.09
Forecast
1Y Price Target
$38.42Price Target Upside122.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
---
Bulls Say, Bears Say
Bulls Say
Demand GrowthOverall injections grew by 4% quarter-over-quarter, which represents the best metric for demand in the space.
Market PositionSyfovre remains the market leader in geographic atrophy with over 60% share, and its share of new patient starts continues to increase.
Potential GrowthSyfovre has blockbuster potential in geographic atrophy over the long term, as its superior efficacy relative to competitor Izervay should ultimately drive significant market share.
Bears Say
Competitive PressureThe biggest potential headwind factor for Syfovre is the full market return of Astellas' Izervay, as they battle for a share of new geographic atrophy patient starts.
Funding IssuesThere is a funding shortage at the co-pay assistance programs, which is unlikely to be resolved soon, potentially increasing the free drug rate and leading to downside for numbers.
Revenue ChallengesApellis reported Syfovre revenue of $130.2 million, well below the estimates and consensus, indicating weaker-than-expected performance.
---
Ownership Overview
3.43% Insiders
21.59% Mutual Funds
0.17% Other Institutional Investors
59.89% Public Companies and
Individual Investors
APLS FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $16.98 and its highest was $44.12 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Apellis Pharmaceuticals Inc’s market cap is $2.40B.
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is Aug 11, 2025 which is in 92 days.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on May 07, 2025. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.344 by -$0.396.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is -0.43.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Apellis Pharmaceuticals Inc has 125,682,260 shares outstanding.
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.344. Following the earnings report the stock price went down -5.91%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in APLS
---
Apellis Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.42 (122.08% Upside)
$38.42 (122.08% Upside)
Blogger Sentiment
Bullish
APLS Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 8.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $154.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.82%
12-Months-Change
Fundamentals
Return on Equity
-103.82%
Trailing 12-Months
Asset Growth
12.21%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
---
APLS Company Deck
---
APLS Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with notable achievements such as FDA Priority Review for EMPAVELI and maintaining market leadership with SYFOVRE. However, revenue challenges due to inventory dynamics and funding shortages for co-pay assistance programs were significant concerns.Read More>---
APLS Stock 12 Month Forecast
Average Price Target
$38.42
▲(122.08% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Merus
―
Scholar Rock Holding
―
Crinetics Pharmaceuticals
―
Immunovant
―
---